Cohance Lifesciences Limited CC-Jun25.pdf · 2025-08-13
So, my first question is with regards to the opening remarks on your interaction with the Japanese customer. So, where are we in this discussion now? And do we have any visibility of certain onboarding of certain plans or certain new projects coming in, in the near term?
And just one more on your API business. How does this fit into the entire scheme of things when we are approaching innovators and at the same time we have this generic business? So, what is the perception that the innovators would have when we are into a generic kind of a business or a business model?